Action myoclonus-renal failure syndrome: Characterization of a unique cerebro-renal disorder

AmanPreet Badhwar, Samuel F. Berkovic, John P. Dowling, Michael Gonzales, Sridar Narayanan, Amy Brodtmann, Leon Berzen, John Nathaniel Caviness, Claudia Trenkwalder, Juliane Winkelmann, Jean Rivest, Mari Lambert, Otto Hernandez-Cossio, Stirling Carpenter, Frederick Andermann, Eva Andermann

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Action myoclonus-renal failure syndrome (AMRF) is a distinctive form of progressive myoclonus epilepsy associated with renal dysfunction. The syndrome was not recognized prior to the advent of dialysis and renal transplantation because of its rapidly fatal course if renal failure is untreated. The first and only description of AMRF was in four French Canadian patients in three families (Andermann et al., 1986). We now describe 15 individuals with AMRF from five countries, including a follow- up of the four French Canadian patients, allowing a more complete characterization of this disease. Our 15 patients with AMRF belong to nine different families. Segregation analyses were compatible with autosomal recessive inheritance. In addition, our findings show that AMRF can present with either renal or neurological features. Tremor (onset 17-26 years, mean 19.8 years, median 19 years) and progressively disabling action myoclonus (onset 14-29 years, mean 21.7 years, median 21 years), with infrequent generalized seizures (onset 20- 28 years, mean 22.7 years, median 22 years) and cerebellar features are characteristic. Proteinuria, detected between ages 9 and 30 years in all cases, progressed to renal failure in 12 out of 15 patients within 0-8 years after proteinuria detection. Brain autopsy in two patients revealed extraneuronal pigment accumulation. Renal biopsies showed collapsing glomerulopathy, a severe variant of focal glomerulosclerosis. This study extends the AMRF phenotype, and demonstrates a more extensive ethnic and geographic distribution of a syndrome originally believed to be confined to individuals of French Canadian ancestry. The independent progression of neurological and renal disorders in AMRF suggests a unitary molecular lesion with pleiotropic effects. Our results demonstrate that the renal lesion in AMRF is a recessive form of collapsing glomerulopathy. Genes identified for focal segmental glomerulosclerosis and involved with the function of the glomerular basement membrane and related proteins are thus good candidates. Treatment can improve quality of life and extend the lifespan of these patients. Dialysis and renal transplantation are effective for the renal but not the neurological features, which continue to progress even in the presence of normalized renal function; the latter can be managed with anti-myoclonic and anti-epileptic drugs.

Original languageEnglish (US)
Pages (from-to)2173-2182
Number of pages10
JournalBrain
Volume127
Issue number10
DOIs
StatePublished - Oct 2004

Fingerprint

Progressive Myoclonic Epilepsy
Kidney
Focal Segmental Glomerulosclerosis
Proteinuria
Kidney Transplantation
Renal Insufficiency
Dialysis
Glomerular Basement Membrane
Myoclonus
Tremor
Nervous System Diseases
Autopsy
Membrane Proteins
Seizures
Quality of Life

Keywords

  • Action myoclonus
  • Autosomal recessive inheritance
  • Cerebro-renal disorder
  • Progressive myoclonus epilepsy
  • Renal failure

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Badhwar, A., Berkovic, S. F., Dowling, J. P., Gonzales, M., Narayanan, S., Brodtmann, A., ... Andermann, E. (2004). Action myoclonus-renal failure syndrome: Characterization of a unique cerebro-renal disorder. Brain, 127(10), 2173-2182. https://doi.org/10.1093/brain/awh263

Action myoclonus-renal failure syndrome : Characterization of a unique cerebro-renal disorder. / Badhwar, AmanPreet; Berkovic, Samuel F.; Dowling, John P.; Gonzales, Michael; Narayanan, Sridar; Brodtmann, Amy; Berzen, Leon; Caviness, John Nathaniel; Trenkwalder, Claudia; Winkelmann, Juliane; Rivest, Jean; Lambert, Mari; Hernandez-Cossio, Otto; Carpenter, Stirling; Andermann, Frederick; Andermann, Eva.

In: Brain, Vol. 127, No. 10, 10.2004, p. 2173-2182.

Research output: Contribution to journalArticle

Badhwar, A, Berkovic, SF, Dowling, JP, Gonzales, M, Narayanan, S, Brodtmann, A, Berzen, L, Caviness, JN, Trenkwalder, C, Winkelmann, J, Rivest, J, Lambert, M, Hernandez-Cossio, O, Carpenter, S, Andermann, F & Andermann, E 2004, 'Action myoclonus-renal failure syndrome: Characterization of a unique cerebro-renal disorder', Brain, vol. 127, no. 10, pp. 2173-2182. https://doi.org/10.1093/brain/awh263
Badhwar A, Berkovic SF, Dowling JP, Gonzales M, Narayanan S, Brodtmann A et al. Action myoclonus-renal failure syndrome: Characterization of a unique cerebro-renal disorder. Brain. 2004 Oct;127(10):2173-2182. https://doi.org/10.1093/brain/awh263
Badhwar, AmanPreet ; Berkovic, Samuel F. ; Dowling, John P. ; Gonzales, Michael ; Narayanan, Sridar ; Brodtmann, Amy ; Berzen, Leon ; Caviness, John Nathaniel ; Trenkwalder, Claudia ; Winkelmann, Juliane ; Rivest, Jean ; Lambert, Mari ; Hernandez-Cossio, Otto ; Carpenter, Stirling ; Andermann, Frederick ; Andermann, Eva. / Action myoclonus-renal failure syndrome : Characterization of a unique cerebro-renal disorder. In: Brain. 2004 ; Vol. 127, No. 10. pp. 2173-2182.
@article{aa76c94095c2453e9dcc77af813fb005,
title = "Action myoclonus-renal failure syndrome: Characterization of a unique cerebro-renal disorder",
abstract = "Action myoclonus-renal failure syndrome (AMRF) is a distinctive form of progressive myoclonus epilepsy associated with renal dysfunction. The syndrome was not recognized prior to the advent of dialysis and renal transplantation because of its rapidly fatal course if renal failure is untreated. The first and only description of AMRF was in four French Canadian patients in three families (Andermann et al., 1986). We now describe 15 individuals with AMRF from five countries, including a follow- up of the four French Canadian patients, allowing a more complete characterization of this disease. Our 15 patients with AMRF belong to nine different families. Segregation analyses were compatible with autosomal recessive inheritance. In addition, our findings show that AMRF can present with either renal or neurological features. Tremor (onset 17-26 years, mean 19.8 years, median 19 years) and progressively disabling action myoclonus (onset 14-29 years, mean 21.7 years, median 21 years), with infrequent generalized seizures (onset 20- 28 years, mean 22.7 years, median 22 years) and cerebellar features are characteristic. Proteinuria, detected between ages 9 and 30 years in all cases, progressed to renal failure in 12 out of 15 patients within 0-8 years after proteinuria detection. Brain autopsy in two patients revealed extraneuronal pigment accumulation. Renal biopsies showed collapsing glomerulopathy, a severe variant of focal glomerulosclerosis. This study extends the AMRF phenotype, and demonstrates a more extensive ethnic and geographic distribution of a syndrome originally believed to be confined to individuals of French Canadian ancestry. The independent progression of neurological and renal disorders in AMRF suggests a unitary molecular lesion with pleiotropic effects. Our results demonstrate that the renal lesion in AMRF is a recessive form of collapsing glomerulopathy. Genes identified for focal segmental glomerulosclerosis and involved with the function of the glomerular basement membrane and related proteins are thus good candidates. Treatment can improve quality of life and extend the lifespan of these patients. Dialysis and renal transplantation are effective for the renal but not the neurological features, which continue to progress even in the presence of normalized renal function; the latter can be managed with anti-myoclonic and anti-epileptic drugs.",
keywords = "Action myoclonus, Autosomal recessive inheritance, Cerebro-renal disorder, Progressive myoclonus epilepsy, Renal failure",
author = "AmanPreet Badhwar and Berkovic, {Samuel F.} and Dowling, {John P.} and Michael Gonzales and Sridar Narayanan and Amy Brodtmann and Leon Berzen and Caviness, {John Nathaniel} and Claudia Trenkwalder and Juliane Winkelmann and Jean Rivest and Mari Lambert and Otto Hernandez-Cossio and Stirling Carpenter and Frederick Andermann and Eva Andermann",
year = "2004",
month = "10",
doi = "10.1093/brain/awh263",
language = "English (US)",
volume = "127",
pages = "2173--2182",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Action myoclonus-renal failure syndrome

T2 - Characterization of a unique cerebro-renal disorder

AU - Badhwar, AmanPreet

AU - Berkovic, Samuel F.

AU - Dowling, John P.

AU - Gonzales, Michael

AU - Narayanan, Sridar

AU - Brodtmann, Amy

AU - Berzen, Leon

AU - Caviness, John Nathaniel

AU - Trenkwalder, Claudia

AU - Winkelmann, Juliane

AU - Rivest, Jean

AU - Lambert, Mari

AU - Hernandez-Cossio, Otto

AU - Carpenter, Stirling

AU - Andermann, Frederick

AU - Andermann, Eva

PY - 2004/10

Y1 - 2004/10

N2 - Action myoclonus-renal failure syndrome (AMRF) is a distinctive form of progressive myoclonus epilepsy associated with renal dysfunction. The syndrome was not recognized prior to the advent of dialysis and renal transplantation because of its rapidly fatal course if renal failure is untreated. The first and only description of AMRF was in four French Canadian patients in three families (Andermann et al., 1986). We now describe 15 individuals with AMRF from five countries, including a follow- up of the four French Canadian patients, allowing a more complete characterization of this disease. Our 15 patients with AMRF belong to nine different families. Segregation analyses were compatible with autosomal recessive inheritance. In addition, our findings show that AMRF can present with either renal or neurological features. Tremor (onset 17-26 years, mean 19.8 years, median 19 years) and progressively disabling action myoclonus (onset 14-29 years, mean 21.7 years, median 21 years), with infrequent generalized seizures (onset 20- 28 years, mean 22.7 years, median 22 years) and cerebellar features are characteristic. Proteinuria, detected between ages 9 and 30 years in all cases, progressed to renal failure in 12 out of 15 patients within 0-8 years after proteinuria detection. Brain autopsy in two patients revealed extraneuronal pigment accumulation. Renal biopsies showed collapsing glomerulopathy, a severe variant of focal glomerulosclerosis. This study extends the AMRF phenotype, and demonstrates a more extensive ethnic and geographic distribution of a syndrome originally believed to be confined to individuals of French Canadian ancestry. The independent progression of neurological and renal disorders in AMRF suggests a unitary molecular lesion with pleiotropic effects. Our results demonstrate that the renal lesion in AMRF is a recessive form of collapsing glomerulopathy. Genes identified for focal segmental glomerulosclerosis and involved with the function of the glomerular basement membrane and related proteins are thus good candidates. Treatment can improve quality of life and extend the lifespan of these patients. Dialysis and renal transplantation are effective for the renal but not the neurological features, which continue to progress even in the presence of normalized renal function; the latter can be managed with anti-myoclonic and anti-epileptic drugs.

AB - Action myoclonus-renal failure syndrome (AMRF) is a distinctive form of progressive myoclonus epilepsy associated with renal dysfunction. The syndrome was not recognized prior to the advent of dialysis and renal transplantation because of its rapidly fatal course if renal failure is untreated. The first and only description of AMRF was in four French Canadian patients in three families (Andermann et al., 1986). We now describe 15 individuals with AMRF from five countries, including a follow- up of the four French Canadian patients, allowing a more complete characterization of this disease. Our 15 patients with AMRF belong to nine different families. Segregation analyses were compatible with autosomal recessive inheritance. In addition, our findings show that AMRF can present with either renal or neurological features. Tremor (onset 17-26 years, mean 19.8 years, median 19 years) and progressively disabling action myoclonus (onset 14-29 years, mean 21.7 years, median 21 years), with infrequent generalized seizures (onset 20- 28 years, mean 22.7 years, median 22 years) and cerebellar features are characteristic. Proteinuria, detected between ages 9 and 30 years in all cases, progressed to renal failure in 12 out of 15 patients within 0-8 years after proteinuria detection. Brain autopsy in two patients revealed extraneuronal pigment accumulation. Renal biopsies showed collapsing glomerulopathy, a severe variant of focal glomerulosclerosis. This study extends the AMRF phenotype, and demonstrates a more extensive ethnic and geographic distribution of a syndrome originally believed to be confined to individuals of French Canadian ancestry. The independent progression of neurological and renal disorders in AMRF suggests a unitary molecular lesion with pleiotropic effects. Our results demonstrate that the renal lesion in AMRF is a recessive form of collapsing glomerulopathy. Genes identified for focal segmental glomerulosclerosis and involved with the function of the glomerular basement membrane and related proteins are thus good candidates. Treatment can improve quality of life and extend the lifespan of these patients. Dialysis and renal transplantation are effective for the renal but not the neurological features, which continue to progress even in the presence of normalized renal function; the latter can be managed with anti-myoclonic and anti-epileptic drugs.

KW - Action myoclonus

KW - Autosomal recessive inheritance

KW - Cerebro-renal disorder

KW - Progressive myoclonus epilepsy

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=4944242282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4944242282&partnerID=8YFLogxK

U2 - 10.1093/brain/awh263

DO - 10.1093/brain/awh263

M3 - Article

C2 - 15364701

AN - SCOPUS:4944242282

VL - 127

SP - 2173

EP - 2182

JO - Brain

JF - Brain

SN - 0006-8950

IS - 10

ER -